Skip to main content

99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping Over $250

Menu

Kynetide Research Team | 2 days ago

New Real-World Study Links Tirzepatide to Fewer Heart Attacks in Type 2 Diabetes

Tirzepatide is best known for its glucose- and weight-lowering effects, but a newly published study adds evidence for another benefit: a real reduction in serious cardiovascular events. Published in The British Medical Journal, it's one of the largest real-world looks yet at how tirzepatide performs on cardiovascular outcomes outside a clinical trial setting.

The Setup, The Data, and The Caveats

The Setup: Tirzepatide acts on two incretin pathways at once, the GIP and GLP-1 receptors, and while it has consistently shown benefits for heart failure hospitalization and overall mortality, its effect on broader events like heart attacks and stroke has been harder to pin down since most large trials compare it to other active drugs rather than a placebo. To get around that gap, researchers used a claims-data approach, comparing tirzepatide against sitagliptin, a diabetes drug whose cardiovascular neutrality was already established in placebo-controlled trials, effectively using it as a placebo stand-in.


The Data: Drawing on two U.S. insurance claims databases from 2022 to 2025, researchers tracked more than 52,000 adults with type 2 diabetes and existing atherosclerotic cardiovascular disease for up to a year after starting either drug. After statistically balancing the two groups, those started on tirzepatide had a one-year risk of major cardiovascular events of 2.9%, versus 4.4% for sitagliptin, a 32% lower relative hazard, driven mainly by fewer heart attacks and lower overall mortality.


The Caveats: Stroke risk didn't differ meaningfully between the two groups, and the authors flagged real limitations: a relatively short follow-up (a median of under six months on treatment), the use of an active drug as a placebo stand-in, and the usual risk of hidden bias in claims-based data. Still, the results track with earlier trial data on tirzepatide's cardiovascular benefits and give clinicians another real-world data point as its use keeps expanding beyond diabetes care.


Source: News-Medical / The British Medical Journal, Aug 10, 2026

Let’s create what matters — together.

Kynetide Research Team

More Posts

Rice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery SystemsRice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery Systems
Rice Engineers Find a Way to Make Peptides Stay Put Longer in Gelatin Delivery Systems

Peptides are prized for their ability to drive specific biological processes like bone formation and tissue repair, but their small size has always worked against them in drug delivery: once placed in water-rich materials like hydrogels, they tend to diffuse away long before healing is complete. A new Rice University study, published in Cell Biomaterials, offers a surprisingly simple fix.

Aug 9 | Kynetide Research Team
A Harvard Medical Perspective on the Peptide BoomA Harvard Medical Perspective on the Peptide Boom
A Harvard Medical Perspective on the Peptide Boom

Harvard Health Publishing recently examined the fast-growing world of injectable peptides, from FDA-approved medications like insulin and GLP-1 drugs to the unregulated compounds sold online for research and personal use. Their findings offer a useful checkpoint for anyone following the peptide space, including everyone in our own research community.

Aug 7 | Kynetide Research Team
A New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for ResearchersA New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for Researchers
A New Accreditation Body Wants to Standardize Peptide Quality — Here's What It Means for Researchers

A new nonprofit is building the first peptide-specific accreditation standards for compounding and sourcing, just as regulators weigh whether to expand access to several popular research peptides.

Aug 5 | Kynetide Research Team
Inside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing BackInside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing Back
Inside the Peptide Controversy: Why FDA Scientists and Critics Are Pushing Back

The FDA advisory panel's vote to ease restrictions on six peptides made headlines this week. But the vote wasn't as clear-cut as the headlines suggest. Behind the scenes, FDA's own scientific staff recommended against it, several panel members have documented industry ties, and the peptides in question are already circulating on the unregulated gray market. Here's what the coverage is missing.

Aug 5 | Kynetide Research Team
Peptides Still Aren't Legal: What the FDA Advisory Panel Vote Actually MeansPeptides Still Aren't Legal: What the FDA Advisory Panel Vote Actually Means
Peptides Still Aren't Legal: What the FDA Advisory Panel Vote Actually Means

Last month's FDA advisory panel vote on peptide compounding made headlines everywhere — but it's created almost as much confusion as clarity. Here's what actually changed, what hasn't, and what to expect next.

Aug 4 | Kynetide Research Team
5 Red Flags to Watch For When Choosing a Research Peptide Supplier5 Red Flags to Watch For When Choosing a Research Peptide Supplier
5 Red Flags to Watch For When Choosing a Research Peptide Supplier

With regulatory attention on peptide purity and sourcing higher than ever, knowing how to evaluate a supplier yourself is one of the most useful skills a researcher can have. Here are five warning signs that should make you think twice before ordering.

Aug 4 | Kynetide Research Team
FDA Advisory Panel Backs Six Peptides for Compounding: What It Means for the Research MarketFDA Advisory Panel Backs Six Peptides for Compounding: What It Means for the Research Market
FDA Advisory Panel Backs Six Peptides for Compounding: What It Means for the Research Market

A look at the FDA's July 2026 compounding-committee vote on six popular peptides, the safety concerns it has raised among the agency's own scientists and patient-safety groups, and why verified, lab-tested sourcing still matters most.

Aug 3 | Kynetide Research Team
Peptide Stacking 101: Combining Research Peptides SafelyPeptide Stacking 101: Combining Research Peptides Safely
Peptide Stacking 101: Combining Research Peptides Safely

Many research protocols call for combining more than one peptide at a time, but stacking introduces its own set of variables beyond what a single-compound study requires. This guide covers the basics of peptide stacking: why researchers combine compounds, how to think about complementary mechanisms, timing and injection site considerations when multiple peptides are in use, and the documentation habits that keep a multi-compound protocol interpretable.

Aug 2 | Jane Smith
Peptide Injection Technique 101: Sites, Needles, and TechniquePeptide Injection Technique 101: Sites, Needles, and Technique
Peptide Injection Technique 101: Sites, Needles, and Technique

Reconstituting and dosing a peptide correctly only gets a researcher halfway there — the injection itself matters just as much. This guide covers subcutaneous injection basics for research peptides: choosing an appropriate site, needle gauge and length considerations, site rotation to avoid tissue irritation, and the common technique mistakes that can affect a study's consistency.

Aug 1 | Jane Smith